Scott J. Rodig

78.5k citations
349 papers · 34.2k · 25 hit papers · h-index 85

Impact in

  • Oncology top 0.02%
    • Cancer Immunotherapy and Biomarkers
    • CAR-T cell therapy research
    • Viral-associated cancers and disorders
  • Immunology top 0.05%
    • Immune Cell Function and Interaction
    • Immunotherapy and Immune Responses

Papers in

Scott J. Rodig

329 papers receiving 33.8k citations

Scott J. Rodig's Hit Papers

Nivolumab for Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Patients Ineligible for or Having Failed Autologous Transplantation: A Single-Arm, Phase II Study 2019 · 253 citations
2530+4+9Years since publication50010001.5k2.0k2.5k

Peers

Scott J. Rodig
Comparison fields: 5 of 149
  • Oncology 16.1k
  • Immunology 9.9k
  • Pathology and Forensic Medicine 7.4k
  • Genetics 3.5k
  • Cancer Research 3.6k
Replace Ash A. Alizadeh with:
Ash A. Alizadeh United States
Elı́as Campo Spain
Mark Raffeld United States
Claudio Doglioni Italy
Giorgio Inghirami United States
Anas Younes United States
William C. Hahn United States
Julian Downward United Kingdom
Reinhard Dummer Switzerland
Brunangelo Falini Italy
Scott J. Rodig relative to Ash A. Alizadeh United States Ash A. Alizadeh's profile →
Citations per field
00.5×1.5×2.4×
Ash A. Alizadeh · 1×
Citations per year

Countries citing papers authored by Scott J. Rodig

Since Specialization
Citations

This map shows the geographic impact of Scott J. Rodig's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Scott J. Rodig with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Scott J. Rodig more than expected).

Fields of papers citing papers by Scott J. Rodig

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Scott J. Rodig. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Scott J. Rodig. The network helps show where Scott J. Rodig may publish in the future.

Co-authors

The 25 scholars most cited alongside Scott J. Rodig, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Scott J. Rodig Line = papers co-authored together Scott J. Rodig links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 349 papers — load more, or switch the sort, to bring in the rest.

#Work
1
PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
Hit paper breakdown →
20142687
2
Comprehensive analyses of tumor immunity: implications for cancer immunotherapy
Hit paper breakdown →
20161644
3
Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK
Hit paper breakdown →
20091469
4
Targeted Disruption of the Stat1 Gene in Mice Reveals Unexpected Physiologic Specificity in the JAK–STAT Signaling Pathway
Hit paper breakdown →
19961414
5
Adaptive immunity maintains occult cancer in an equilibrium state
Hit paper breakdown →
20071026
6
Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma
Hit paper breakdown →
2010939
7
MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
Hit paper breakdown →
2012807
8
Disruption of the Jak1 Gene Demonstrates Obligatory and Nonredundant Roles of the Jaks in Cytokine-Induced Biologic Responses
Hit paper breakdown →
1998675
9
PD-L1 Expression Is Characteristic of a Subset of Aggressive B-cell Lymphomas and Virus-Associated Malignancies
Hit paper breakdown →
2013666
10
Tet1 and Tet2 Regulate 5-Hydroxymethylcytosine Production and Cell Lineage Specification in Mouse Embryonic Stem Cells
Hit paper breakdown →
2011610
11
Crizotinib inALK-Rearranged Inflammatory Myofibroblastic Tumor
Hit paper breakdown →
2010608
12
PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Hit paper breakdown →
2016563
13
Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell Lymphoma
Hit paper breakdown →
2013560
14
Constitutive AP-1 Activity and EBV Infection Induce PD-L1 in Hodgkin Lymphomas and Posttransplant Lymphoproliferative Disorders: Implications for Targeted Therapy
Hit paper breakdown →
2012559
15
Unique Clinicopathologic Features Characterize ALK -Rearranged Lung Adenocarcinoma in the Western Population
Hit paper breakdown →
2009528
16
Association of Polymerase e–Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1
Hit paper breakdown →
2015525
17
Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma
Hit paper breakdown →
2012489
18
Immunological mechanisms of the antitumor effects of supplemental oxygenation
Hit paper breakdown →
2015486
19
Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer
Hit paper breakdown →
2016456
20
The biology and treatment of EML4-ALK non-small cell lung cancer
Hit paper breakdown →
2010425

About Scott J. Rodig

Scott J. Rodig is a scholar working on Oncology, Molecular Biology, Pathology and Forensic Medicine, Immunology and Pulmonary and Respiratory Medicine, having authored 349 papers that have together received 34.2k indexed citations. Recurring topics across this work include Cancer Immunotherapy and Biomarkers (79 papers), Lymphoma Diagnosis and Treatment (79 papers), CAR-T cell therapy research (37 papers), Immunotherapy and Immune Responses (33 papers), Immune Cell Function and Interaction (32 papers), Chronic Lymphocytic Leukemia Research (26 papers), Cancer Genomics and Diagnostics (22 papers) and Lung Cancer Treatments and Mutations (20 papers). The work is most often cited by research in Oncology (16.1k citations), Immunology (9.9k citations), Pathology and Forensic Medicine (7.4k citations), Genetics (3.5k citations) and Cancer Research (3.6k citations). Scott J. Rodig has collaborated with scholars based in United States, Germany and United Kingdom. Frequent co-authors include Margaret A. Shipp, Bjoern Chapuy, Gordon J. Freeman, Philippe Armand, Donna Neuberg, Robert D. Schreiber, Pasi A. Jänne, Lucian R. Chirieac, Jeffery L. Kutok and Heather H. Sun. Their work appears in journals such as Blood, Journal of Clinical Oncology, Cold Spring Harbor Protocols, Clinical Cancer Research and Cancer Immunology Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact